Security
Evotec SE American Depositary Shares · EVO
EVONASDAQotherCurrentCIK 1412558Updated Nov 16, 2026
EVO price & chart
Loading TradingView…
NASDAQ:EVO on TradingView ↗About the company
Evotec is a life science company pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advanced technologies, Evotec accelerates the journey from concept to cure with greater speed, intelligence and precision. The company's expertise spans small molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms including Molecular Patient Databases, PanOmics and induced pluripotent stem cell-based disease modeling. Through flexible partnering models tailored to customers' needs, Evotec works with all Top 20 pharmaceutical companies, more than 800 biotechnology companies, academic institutions and other healthcare stakeholders. Evotec's offerings range from standalone services to fully integrated research and development programs and long-term strategic partnerships, combining scientific excellence with operational agility. Through Just - Evotec Biologics, the company is redefining biologics development and manufacturing to improve accessibility and affordability. With a portfolio of more than 100 proprietary research and development assets, most of which are co-owned, Evotec focuses…
In the news
Recent filings
Show 5 more recent filings
Financials
FY 2024 · EURSource
Source
Source
cash flow · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Profit or LossEUR | -196,078,000Source | -83,913,000Source | -175,655,000Source | 215,510,000Source |
| Additional Financial Items | ||||
| AdjustmentsForCurrentTaxOfPriorPeriodEUR | -328,000Source | 2,666,000Source | -156,000Source | 4,095,000Source |
| AdjustmentsForDecreaseIncreaseInTradeAccountReceivableEUR | — | — | -38,429,000Source | -48,032,000Source |
| AdjustmentsForGainLossOnDisposalOfInvestmentsInSubsidiariesJointVenturesAndAssociatesEUR | -8,648,000Source | — | — | — |
| AdjustmentsForIncomeTaxExpenseEUR | 2,102,000Source | 3,320,000Source | — | — |
| AdjustmentsForSharebasedPaymentsEUR | 5,035,000Source | 9,630,000Source | 9,919,000Source | 7,805,000Source |
| GoodwillEUR | 282,854,000Source | 275,635,000Source | 274,819,000Source | 257,569,000Source |
| IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesEUR | -76,083,000Source | 12,902,000Source | — | — |
| IncreaseDecreaseInWorkingCapitalEUR | 68,207,000Source | 9,944,000Source | — | — |
| InterestPaidClassifiedAsFinancingActivitiesEUR | 5,920,000Source | 12,853,000Source | — | — |
| InterestPaidClassifiedAsOperatingActivitiesEUR | — | — | 9,798,000Source | 5,429,000Source |
| InterestReceivedClassifiedAsOperatingActivitiesEUR | — | — | 3,026,000Source | 1,106,000Source |
| PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesEUR | 24,124,000Source | 22,446,000Source | 19,046,000Source | 20,665,000Source |
| ProceedsFromBorrowingsClassifiedAsFinancingActivitiesEUR | 900,000Source | 219,923,000Source | — | 30,791,000Source |
| ProceedsFromIssuingSharesEUR | — | — | 355,000Source | 403,126,000Source |
| ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivitiesEUR | 2,000,000Source | 530,000Source | — | — |
| PurchaseOfIntangibleAssetsClassifiedAsInvestingActivitiesEUR | 14,769,000Source | 2,677,000Source | — | — |
| RepaymentsOfBorrowingsClassifiedAsFinancingActivitiesEUR | 128,849,000Source | 112,880,000Source | 34,067,000Source | 16,018,000Source |
income statement · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Cost of Goods and Services Sold | —Source | —Source | —Source | —Source |
| Selling, General and Administrative ExpenseEUR | 188,201,000Source | 169,610,000Source | 156,190,000Source | 105,445,000Source |
| Total RevenueEUR | 796,967,000Source | 781,426,000Source | 751,448,000Source | 618,034,000Source |
| Additional Financial Items | ||||
| ApplicableTaxRatenumber | 0.32Source | 0.32Source | 0.32Source | 0.32Source |
| AverageEffectiveTaxRatenumber | -0.01Source | -0.04Source | -0.14Source | 0.09Source |
| BasicEarningsLossPerShareEUR/shares | -1.11Source | -0.47Source | -0.99Source | 1.3Source |
| CurrentTaxExpenseIncomeEUR | 7,761,000Source | 5,251,000Source | 14,132,000Source | 12,309,000Source |
| DeferredTaxExpenseIncomeRecognisedInProfitOrLossEUR | -5,331,000Source | -4,597,000Source | 7,722,000Source | 5,066,000Source |
| DepreciationRightofuseAssetsEUR | 21,530,000Source | 21,075,000Source | 18,659,000Source | 15,829,000Source |
| DilutedEarningsLossPerShareEUR/shares | -1.11Source | -0.47Source | -0.99Source | 1.3Source |
| EmployeeBenefitsExpenseEUR | 458,738,000Source | 377,587,000Source | 388,050,000Source | 319,353,000Source |
| ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsedEUR | 57,000Source | 62,000Source | 50,000Source | 56,000Source |
| ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsedEUR | 283,000Source | 236,000Source | 476,000Source | 839,000Source |
| GrossProfitEUR | 114,881,000Source | 175,051,000Source | 174,065,000Source | 151,543,000Source |
| ImpairmentLossRecognisedInProfitOrLossGoodwillEUR | 0Source | 0Source | 0Source | 0Source |
| ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwillEUR | — | — | — | 683,000Source |
| IncomeTaxExpenseContinuingOperationsEUR | 2,102,000Source | 3,320,000Source | 21,698,000Source | 21,470,000Source |
| InterestExpenseEUR | — | — | 13,150,000Source | 9,254,000Source |
| InterestExpenseOnLeaseLiabilitiesEUR | 4,727,000Source | 5,831,000Source | 3,841,000Source | 3,728,000Source |
| OtherFinanceCostEUR | 11,699,000Source | 11,739,000Source | — | 198,000Source |
| OtherIncomeEUR | 52,700,000Source | 64,793,000Source | 81,582,000Source | 73,472,000Source |
| ProfitLossAttributableToOwnersOfParentEUR | — | — | -175,655,000Source | 215,510,000Source |
| ProfitLossBeforeTaxEUR | -193,977,000Source | -80,593,000Source | -153,957,000Source | 236,980,000Source |
| ProfitLossFromOperatingActivitiesEUR | -142,522,000Source | -47,507,000Source | 20,850,000Source | 40,996,000Source |
| ResearchAndDevelopmentExpenseEUR | 50,857,000Source | 68,529,000Source | 76,642,000Source | 72,200,000Source |
| RevenueFromInterestEUR | — | — | 8,336,000Source | 2,272,000Source |
Filing attachments
tm2629114d1_ex99-1.htm · 6-K · 2026-11-05
Exhibit 99.1 For further information, please contact: Dr. Sarah Fakih, EVP Head of Global Communications and Investor Relations, sarah.fakih@evotec.com, M. +49.(0)151 70 688 784, www.evotec.com INTERIM STATEMENT 9M 2026 HIGHLIGHTS 4 D&PD LEADING COMMERCIAL INDICATORS SHOW CONTINUED IMPROVEMENT 4 JUST – EVOTEC BIOLOGICS (“JEB”) Q3 PERFORMANCE AFFECTED BY PARTIAL MILESTONE ACHIEVEMENT; FULL-YEAR OUTLOOK IMPACTED BY MILESTONE TIMING, PROJECT SHI…
Read attachment ↗tm2629114d1_ex99-2.htm · 6-K · 2026-11-05
Exhibit 99.2 Evotec Reports Third Quarter and Nine-Month 2026 Results: Building Growth Momentum Toward 2030 Goals Financial performance: Q3 and nine-month Group revenue of €164.9 m and €465.0 m, respectively (Q3: €164.2 m, 9M: €477.4 m at CER); adj. Group EBITDA of -€1.6 m and -€44.3 m, respectively (Q3: -€1.7 m, 9M: -€39.1 m at CER) Robust commercial momentum: Net sales* in D&PD base business increased 24% vs. 9M 2025 accompanied by continued positive development across key comm…
Read attachment ↗tm2627661d1_ex99-1.htm · 6-K · 2026-10-15
Exhibit 99.1 Evotec Appoints Dr. Joanna Holbrook as Chief Scientific Officer and Member of the Management Board Will lead Evotec’s global scientific strategy and drive differentiation across its discovery and development services, technology platforms and proprietary innovation Brings more than 25 years of global experience in pharma, biotechnology and academia Hamburg, Germany, October 15, 2026 - Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) today announced the appointmen…
Read attachment ↗tm2627661d1_ex99-2.htm · 6-K · 2026-10-15
Exhibit 99.2 Notification of Major Holdings Page 1 | 3 Hamburg, Germany 22419 Manfred Eigen Campus / Essener Bogen 7 529900F9KI6OYITO9B12 Evotec SE X Notification of Major Holdings or Correction of a notification of Major Holdings dated 1. Details of issuer (name, address) Name Legal Entity Identifier (LEI) Street, Street number Postal code City 2. Reason for notification (multiple reasons possible) X Acquisition/disposal of shares with voting rights Acquis…
Read attachment ↗tm2627582d1_ex99-1.htm · 6-K · 2026-10-14
Exhibit 99.1 Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014 Ad hoc: Evotec announces preliminary nine-months 2026 results above market expectations, reaffirming full-year 2026 guidance Hamburg, Germany - Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) today announced preliminary unaudited financial results for first nine months of 2026. Full financial results for the third quarter and the first nine months of 2026 will be published on Nov…
Read attachment ↗tm2626558d1_ex99-1.htm · 6-K · 2026-09-29
Exhibit 99.1 Evotec Announces Chief Scientific Officer Transition Dr. Cord Dohrmann to step down as of September 30, 2026 ─────────────────────────────────────────────────────── Search ongoing for a successor Hamburg, Germany, September 29, 2026 - Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) today announced that Chief Scientific Officer (CSO) Dr. Cord Dohrmann will step down effective September 30, 2026. The decision for Dr. Dohrmann to step down from his position was made…
Read attachment ↗